Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $9.00 Average Price Target from Analysts

Senti Biosciences, Inc. (NASDAQ:SNTI) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $9.00.

Several research analysts have recently weighed in on SNTI shares. HC Wainwright initiated coverage on Senti Biosciences in a report on Tuesday, October 14th. They set a “buy” rating and a $12.00 target price on the stock. Leerink Partnrs upgraded Senti Biosciences to a “strong-buy” rating in a research report on Friday, November 21st. Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Leerink Partners started coverage on Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th.

Senti Biosciences Stock Performance

Shares of SNTI stock opened at $1.03 on Friday. Senti Biosciences has a fifty-two week low of $1.03 and a fifty-two week high of $5.10. The stock’s fifty day moving average is $1.50 and its two-hundred day moving average is $1.67. The firm has a market capitalization of $27.08 million, a P/E ratio of -0.31 and a beta of 2.13.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). On average, equities analysts forecast that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Trading of Senti Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SNTI. Citadel Advisors LLC purchased a new stake in shares of Senti Biosciences during the 3rd quarter valued at approximately $117,000. Geode Capital Management LLC raised its position in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of Senti Biosciences in the 2nd quarter valued at $1,883,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.